Lisinopril
ACE inhibitor
The planned first collection
Established medicines. A more human experience.
We are beginning with generic blood pressure medicines clinicians already know — then making the price, evidence, and path to your door easier to understand.
Amlodipine
Calcium channel blocker
Losartan
Angiotensin II receptor blocker
Metoprolol
Beta blocker
Collection map
What we intend to offer — and when.
This roadmap is a plan, not a product catalog. Eligible strengths, dosage forms, launch states, and partner details will be published before ordering opens.
| Medicine | Type | General role | Planned status |
|---|---|---|---|
| Lisinopril | ACE inhibitor | Prescription treatment used for high blood pressure and certain heart conditions | First wave |
| Amlodipine | Calcium channel blocker | Prescription treatment used for high blood pressure and certain forms of angina | First wave |
| Losartan | Angiotensin II receptor blocker | Prescription treatment used for high blood pressure and selected related conditions | First wave |
| Metoprolol | Beta blocker | Prescription treatment used for selected blood pressure, heart, and rhythm conditions | Next |
| Hydrochlorothiazide | Thiazide diuretic | Prescription treatment used for high blood pressure and fluid retention | Next |
| Selected combinations | Lisinopril/HCTZ · Losartan/HCTZ | Two established active ingredients in one prescribed tablet | Future |
General roles are educational summaries, not a complete list of indications, risks, contraindications, or interactions. A licensed clinician and the FDA-approved labeling determine appropriate use.
What “generic” actually means
An FDA-approved generic is not a lesser version of a medicine. FDA requires it to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug and to meet the same scientific quality standards.
Read FDA’s current generic-drug explanation ↗
The product should be familiar. The company around it should feel refreshingly clear.
Quality and evidence
Before launch, Karam intends to identify the FDA-approved products and licensed partners involved, explain the quality pathway in ordinary language, and publish appropriate quality documentation without exposing protected or patient information.
Where a Certificate of Analysis can responsibly be published, we intend to explain what it confirms, who produced it, and what it does not prove. A document without context is not transparency.
Safety before sales
Do not use this website to make treatment decisions.
Never start, stop, skip, split, or change a prescription medicine based on Karam’s marketing pages. Talk with your clinician or pharmacist. If you believe you are having a medical emergency, call 911.
The planned founding price
Our target is one flat $10 price for a 30-day supply of each eligible medicine, with standard shipping included and no membership required. The exact strengths, states, terms, and final price breakdown will be published before sales begin.
First access
Hear when each medicine reaches its next real milestone.
One plainspoken progress note a month. Joining is not an order or a request for medical care.
Unsubscribe anytime. Privacy details.